New imaging agent could sharpen detection of metastatic pancreatic cancer
NCT ID NCT07217717
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 45 times
Summary
This phase 3 trial is testing whether a new radioactive dye called [18F]FAPI-74, used with a PET/CT scan, can better detect if pancreatic cancer has spread to other parts of the body. About 200 adults with pancreatic cancer will receive one dose of the dye and then be scanned. Researchers will compare the scan results to standard methods to see if it is more accurate and safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope National Cancer Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Helios CR Inc./RadNet
RECRUITINGCerritos, California, 90703, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hoag Memorial Hospital
RECRUITINGIrvine, California, 92618, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Icahn School of Medicine at Mount Sinai
NOT_YET_RECRUITINGNew York, New York, 10029, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Indiana University Health University Hospital
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kettering
RECRUITINGKettering, Ohio, 45429, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Moffit Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford University
RECRUITINGStanford, California, 94305, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UCLA
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UMass/Shields
RECRUITINGWorcester, Massachusetts, 01655, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pennsylvania, Perelman School of Medicine
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F]FAPI-74, a radioactive dye for PET imaging
What this could lead to
If successful, this scan could help doctors more accurately detect whether pancreatic cancer has spread, leading to better treatment decisions.
What could go wrong
This is still an experimental imaging test. It may not prove more accurate than current scans, and results are limited to a specific cancer type.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.